目的 探讨鱼腥草滴眼液治疗流行性角结膜炎的疗效和安全性，并进行药物经济学评价。方法 将200例流行性角结膜炎患者随机分为治疗组（150例）和对照组（50例），治疗组给予鱼腥草滴眼液，1滴/次，6次/d，对照组给予复方熊胆滴眼液，用法和用量同治疗组。采用单盲、平行性对照研究，疗程均为10 d。观察2组疗效及不良反应，并运用成本–效果分析法进行药物经济学评价。结果 治疗组和对照组临床愈显率分别为84%、66%，两组比较差异有统计学意义（P＜0.01）；总有效率分别为98%、88%，两组比较差异有统计学意义（P＜0.05）。不良反应发生率差异无统计学意义（P＞0.05），但治疗组成本–效果比低于对照组（P＜0.01）。结论 鱼腥草滴眼液治疗流行性角结膜炎疗效较好，临床应用安全，经济学优势更加明显。

Objective To evaluate the clinical efficacy and safety of Yuxingcao Gutta, an eye drop consisted of Houttuyniae Herba, in the treatment of epidemic keratoconjunctivitis and to evaluate its pharmacoeconomics. Methods The patients with epidemic keratoconjunctivitis (200 cases) were randomly divided into the treatment (150 cases) and control (50 cases) groups, which were administered with Yuxingcao Gutta and Compound Xiongdan Gutta which was an eye drop consisted of Ursi Fel, one drop once for six times daily, respectively. The course of treatment was 10 d, and the single-blind and parallel-controlled contrast studies were adopted. The clinical efficacy and safety of the two groups were observed and evaluated by the cost-effectiveness method of pharmacoeconomics. Results The markedly effective rate in the treatment and control groups were 84% and 66%, respectively, with the significant difference between the two groups (P < 0.01), and the efficacies in the treatment and control groups were 98% and 88%, respectively, with the significant difference between two groups (P < 0.05). There were no differences between the two groups on safety (P > 0.05), but the cost-effectiveness of the treatment group was lower than that of the control group (P < 0.01). Conclusion The clinical efficacy of Yuxingcao Gutta is better in the treatment of epidemic keratoconjunctivitis and the therapeutic effect is reliable and safe, and has more obvious economic advantages.